| Revision as of 13:31, 10 January 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 460518429 of page Tigatuzumab for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Latest revision as of 00:04, 15 June 2023 edit Entranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers169,991 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper |
| Line 1: |
Line 1: |
|
|
{{Short description|Monoclonal antibody}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 450329812 |
|
| verifiedrevid = 470610217 |
|
| image = |
|
| image = |
|
|
|
|
<!--Monoclonal antibody data--> |
|
<!-- Monoclonal antibody data --> |
|
| type = mab |
|
| type = mab |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = zu/o |
|
| source = zu/o |
|
| target = ] (TRAIL-R2) |
|
| target = ] (TRAIL-R2) |
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
|
| metabolism = |
|
| metabolism = |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
|
⚫ |
| CAS_number_Ref = {{cascite|changed|??}} |
| ⚫ |
<!--Identifiers--> |
|
|
⚫ |
| CAS_number = 918127-53-4 |
| ⚫ |
| CAS_number_Ref = {{cascite|correct|??}} |
|
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
| ⚫ |
| CAS_number = <!-- blanked - oldvalue: 918127-53-4 --> |
|
|
|
| UNII = 237GB6IDKO |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
| Line 39: |
Line 38: |
|
| DrugBank = |
|
| DrugBank = |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
⚫ |
| C=6406 | H=9924 | N=1716 | O=2012 | S=46 |
| ⚫ |
<!--Chemical data--> |
|
| ⚫ |
| C=6406 | H=9924 | N=1716 | O=2012 | S=46 |
|
|
| molecular_weight = 144.6 ] |
|
|
}} |
|
}} |
|
|
'''Tigatuzumab''' ('''CS-1008''') is a ]<ref>{{cite web | title = International Nonproprietary Names for Pharmaceutical Substances (INN): List 60 | url =https://www.who.int/medicines/services/inn/RL60prepublication.pdf | work = WHO Drug Information }}</ref> for the treatment of cancer. {{as of|2009|10}}, a ] for the treatment of ],<ref>{{cite journal | journal = NCI Cancer Bulletin | date = 21 April 2009 | volume = 6 | issue = 8 | url = http://www.cancernet.gov/ncicancerbulletin/042109/page3 | archive-url = https://web.archive.org/web/20110728112103/http://www.cancer.gov/aboutnci/ncicancerbulletin/archive/2009/042109/page3 | archive-date = 28 July 2011 | title = Combination Therapy Targets Pancreatic Cancer Stem Cells}}</ref> Phase II trials for ],<ref>{{ClinicalTrialsGov|NCT00969033|CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin}}</ref> non-small cell ],<ref>{{ClinicalTrialsGov|NCT00991796|CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)}}</ref> and ]<ref>{{ClinicalTrialsGov|NCT00945191|Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer}}</ref> have been completed. |
|
|
|
|
|
The drug targets ] (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein with limited expression in normal tissues but overexpressed in many kinds of tumours, including colon, gastric, pancreatic, lung, and cervical.<ref>{{cite web | url = http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=489323 | title = Drug Dictionary: CS-1008 | work = National Cancer Institute }}</ref><ref name = "Ciprotti_2015">{{cite journal | vauthors = Ciprotti M, Tebbutt NC, Lee FT, Lee ST, Gan HK, McKee DC, O'Keefe GJ, Gong SJ, Chong G, Hopkins W, Chappell B, Scott FE, Brechbiel MW, Tse AN, Jansen M, Matsumura M, Kotsuma M, Watanabe R, Venhaus R, Beckman RA, Greenberg J, Scott AM | display-authors = 6 | title = Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer | journal = Journal of Clinical Oncology | volume = 33 | issue = 24 | pages = 2609–16 | date = August 2015 | pmid = 26124477 | doi = 10.1200/JCO.2014.60.4256 | pmc = 4881374 }}</ref> |
|
|
|
|
|
In 2015, a ] study was completed to investigate how ], quantitative tumor uptake, and antitumor response in patients with metastatic ] was impacted by CS-1008. These objectives were tracked through use of trace-labeling and ] imaging over the course of treatment and found heterogeneity of tigatuzumab uptake in tumors, that tigatuzumab uptake is not dose dependent, and that tigatuzumab uptake is predictive of clinical response in the treatment of metastatic colorectal cancer.<ref name = "Ciprotti_2015" /> |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
{{Monoclonals for tumors}} |
|
|
|
|
|
] |
|
|
|
|
|
{{monoclonal-antibody-stub}} |
|
|
{{antineoplastic-drug-stub}} |